Octreotide
(Somatostatin)ApprovedSmall molecule
Johnson & JohnsonSomatostatin is used to treat certain hormone-producing tumors and control severe diarrhea and flushing caused by specific cancers. It works by reducing the amount of hormones your body produces that cause these symptoms.[2] Octreotide is currently approved and in use across 20 indications[4].[1]
Octreotide is one of 492 small molecule programs targeting Acute Pancreatitis. It is currently in Approved.
20
Indications
33
Total Trials
4
Active Trials
491
Competitors
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 20 indications
Competition
Competitive Landscape
1399 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Octreotide
Johnson & JohnsonApproved
Novantrone
PfizerPreclinical
Mekinist
NovartisPreclinical
Trexall
Alnylam PharmaceuticalsPreclinical
Duragesic
CCephalon
Preclinical
Viagra
VViatris Specialty LLC
Preclinical
Ranexa
MMenarini International Operations Luxembourg SA
Preclinical
Triptorelin Pamoate
IpsenPreclinical
Ifex
BBaxter Healthcare Corporation
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metabolism3 trials
Hypoglycemia2 trials
Liver Transplant2 trials
Hepatocellular Carcinoma2 trials
23 more indications
Gastric Varices1 trial
Insulin Secretion1 trial
Liver Failure1 trial
Pancreatitis1 trial
Gastric Cancer1 trial
Gallbladder Carcinoma1 trial
Gastrointestinal hemorrhage1 trial
Bleeding1 trial
Liver Resection1 trial
Postoperative Pancreatic Fistula1 trial
Small Bowel Obstruction1 trial
Pancreaticoduodenectomy1 trial
Acute Variceal Bleeding1 trial
Gastrointestinal1 trial
Metabolic Consequences of Gastrointestinal Surgery
Terminated·—·N/A·NCT02836353·81 enrolled
Acute Kidney Injury1 trial
Terlipression Prevent Developing of Acute Kidney Injury During Upper-gastroentestinal Bleeding
Completed·—·Phase 4·NCT04358016·54 enrolled
Prostate Cancer1 trial
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Octreotide drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Somatostatin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Somatostatin Receptor Agonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company